Premium
The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine‐induced dopamine elevations in the nucleus accumbens shell in rats
Author(s) -
Scherma Maria,
Justinová Zuzana,
Zanettini Claudio,
Panlilio Leigh V,
Mascia Paola,
Fadda Paola,
Fratta Walter,
Makriyannis Alexandros,
Vadivel Subramanian K,
Gamaleddin Islam,
Le Foll Bernard,
Goldberg Steven R
Publication year - 2012
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2011.01467.x
Subject(s) - nucleus accumbens , nicotine , dopamine , pharmacology , chemistry , endocannabinoid system , neuroscience , anandamide , endocrinology , medicine , psychology , cannabinoid receptor , receptor , agonist
The fatty acid amide hydrolase inhibitor URB597 can reverse the abuse-related behavioural and neurochemical effects of nicotine in rats. Fatty acid amide hydrolase inhibitors block the degradation (and thereby magnify and prolong the actions) of the endocannabinoid anandamide (AEA), and also the non-cannabinoid fatty acid ethanolamides oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). OEA and PEA are endogenous ligands for peroxisome proliferator-activated receptors alpha (PPAR-α). Since recent evidence indicates that PPAR-α can modulate nicotine reward, it is unclear whether AEA plays a role in the effects of URB597 on nicotine reward.